Norwich Ventures
VC Fund
Cambridge, United States
Norwich Ventures is a specialized venture capital firm focused on early-stage medtech. We invest in entrepreneurs developing game-changing technologies that solve large unmet medical needs. We provide initial capital in seed and early-stage rounds. We approach each investment with a long-term perspective and continue to support and invest in thecompany throughout its phases of growth.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 26%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Norwich Ventures invests in
Stages Norwich Ventures invests in
Countries Norwich Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aaron Sandoski
|
|||
|
Janis Sebastian
|
|||
Marlin Miller
|
|||
Philip Fleck
|
|||
Investment Focus
Industry
- Health Care 12 (63%)
- Medical Device 9 (47%)
- Medical 8 (42%)
- Biotechnology 5 (26%)
- Manufacturing 3 (16%)
Stage
- Series A 9 (47%)
- Series B 4 (21%)
- Debt Financing 2 (11%)
- Series C 1 (5%)
- Series D 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Aaron Sandoski
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 7 | Find email | |
|
Janis Sebastian
Office Administrator
|
Office Administrator | Total investments: 0 | Find email | |
|
Marlin Miller
Co-founder and Senior Advisor
|
Co-founder and Senior Advisor | Total investments: 0 | Find email | |
|
Philip Fleck
Director
|
Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ionpath
|
Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health. | $18M / Series B / Sep 24, 2020 | |
Podimetrics
|
Podimetrics is a care management company with the leading solution to help prevent diabetic foot ulcers (DFU), one of the most debilitating and costly complications of diabetes. On behalf of payers and at-risk providers, we send high-risk patients our FDA-cleared, cellular-connected SmartMat. After placing their feet on the mat for just 20 secondsa day, patients’ data are automatically sent to our care management team that triages any concerning findings. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients and allows clinicians to achieve unparalleled outcomes saving limbs, lives, and money. Founded in 2011 by a physician and engineers from MIT and Harvard, Podimetrics is headquartered in Somerville, MA and backed by Norwich Ventures, Scientific Health Development, and Rock Health. For more information, go to www.podimetrics.com or follow us on Twitter @podimetrics. | $8M / Series B / Aug 19, 2020 | |
|
Podimetrics
|
Podimetrics is a care management company with the leading solution to help prevent diabetic foot ulcers (DFU), one of the most debilitating and costly complications of diabetes. On behalf of payers and at-risk providers, we send high-risk patients our FDA-cleared, cellular-connected SmartMat. After placing their feet on the mat for just 20 secondsa day, patients’ data are automatically sent to our care management team that triages any concerning findings. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients and allows clinicians to achieve unparalleled outcomes saving limbs, lives, and money. Founded in 2011 by a physician and engineers from MIT and Harvard, Podimetrics is headquartered in Somerville, MA and backed by Norwich Ventures, Scientific Health Development, and Rock Health. For more information, go to www.podimetrics.com or follow us on Twitter @podimetrics. | $13.4M / Series B / May 09, 2019 | |
ReThink Medical
|
ReThink Medical is a medical device and digital health company developing a wrist-worn monitoring device. Our technology is designed to predict and prevent heart failure hospitalizations through compliance-centric continuous physiologic monitoring & machine learning. Our product, CorBand™ uses state of the art algorithms and artificialintelligence to potentially detect worsening conditions weeks in advance - even before noticeable symptoms. Data-driven therapy can allow ample time for proper treatment to prevent hospitalization, improve quality of life, and save billions in healthcare costs. We've designed a proactive approach to managing heart failure patients with a focus on compliance, simplicity, and accuracy. | $3.5M / Series A / May 01, 2017 | |
Affera, Inc.
|
Affera is a medical technology company dedicated to developing innovative solutions for the treatment of cardiac arrhythmia, a prevalent condition affecting millions of patients worldwide. | Series A / Feb 01, 2017 | |
Pelvalon
|
Pelvalon is a medical device company that develops products for women suffering from fecal incontinence. They help women achieve bowel control. | $3M / Series C / Nov 28, 2016 | |
Lexington Medical, Inc.
|
We are a Boston-based medical device company that manufactures minimally invasive surgical stapling solutions. With the highest standards in design engineering and smart manufacturing, our specialized team is committed to delivering disruptive innovation to health care providers and their patients. | Series A / Nov 01, 2016 | |
Soffio Medical
|
Soffio Medical is a medical company that develops medical apparatus for respiratory diseases. The company is based in Boston, Massachusetts. | Series A / Mar 31, 2016 | |
Arterys
|
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions. | $5M / Series A / Mar 14, 2016 | |
|
Arterys
|
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions. | $7M / Series A / Dec 07, 2015 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Norwich Ventures invest in?
Norwich Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Norwich Ventures?
Public channels for Norwich Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Norwich Ventures?
The team at Norwich Ventures includes Aaron Sandoski (Co-Founder and Managing Director), Janis Sebastian (Office Administrator) and Marlin Miller (Co-founder and Senior Advisor). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
